Leucid Bio
Marc Davies is an experienced immunologist and molecular biologist with over ten years in adoptive T-cell immunotherapy and cancer immunology. Currently serving as VP of R&D and consultant at Leucid Bio since August 2017, Marc specializes in developing CAR T-cell therapies for solid tumors. As a Post-doctoral Research Scientist in T-cell Immunotherapy at King's College London since January 2015, expertise includes designing and pre-clinically assessing CAR and TCR-engineered therapies for various cancers. Previously, Marc worked at UCL from October 2010 to December 2014, focusing on CAR T-cells targeting novel antigens and developing viral envelopes for T-cell transduction. Educational qualifications include a PhD in T-cell Immunotherapy from King's College London and a BSc in Molecular Biology and Biochemistry from Durham University.
This person is not in any teams
This person is not in any offices
Leucid Bio
1 followers
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.